Conditions: Healthy
Allocation: RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 12
Healthy volunteers: yes

Brief summary:
The primary objective of this trial is to investigate the safety and tolerability of multiple doses of BI 655064 following weekly subcutaneous injection for 4 weeks in healthy Chinese male volunteers.

The secondary objective is the exploratory evaluation of the pharmacokinetics and pharmacodynamics of multiple doses of BI 655064 following weekly subcutaneous injection for 4 weeks in healthy Chinese male volunteers.

Detailed description:

Arms:
arm 1: Subjects received BI 655064 240 milligram (mg) via subcutaneous injection every week, until 4 weeks. arm 2: Subjects received placebo matching to BI 655064 via subcutaneous injection every week, until 4 weeks.

Interventions: intervention 1: BI 655064 intervention 2: Placebo
Intervention descriptions: intervention 1: subcutaneous injection intervention 2: Placebo

Protocol document: